Claire D’Abreau-Hayling became Chief Scientific Officer at Sandoz in July 2022 following over 30 years as a pharmaceutical executive with a deep knowledge of drug product development and global R&D processes. She is also a member of the company’s Executive Committee. Prior to assuming her current role, she held the position of Head of Product Development at Sandoz’ headquarters in Basel.
Life before Sandoz saw Claire spend 15 years at Teva Pharmaceuticals in the United Kingdom where she held the positions of Senior Vice President, Global Sterile R&D and Senior Vice President, European R&D Regional Head. She has also previously worked with Sanofi and GSK during the early stages of her career.
As a champion of diversity and inclusion, Claire regularly mentors young women, particularly from Black and Asian backgrounds, who are pursuing careers in STEM. She has therefore developed a reputation as a highly respected and passionate leader of a culturally diverse organization with over 1,800 associates globally that inspire a global vision.
As a proud West Indian, black and female STEM professional, I believe it is my responsibility to pave the path for others to follow. By championing these causes, morale within an organization will markedly improve, with increased transparency around what it takes to advance and awareness of the equal opportunity to do so, irrespective of gender or background.
Before embarking on her career in the pharmaceutical industry, Claire earned a Bachelor of Science in Chemistry degree from the University of the West Indies in Trinidad & Tobago, later supplementing her education with a Master of Science in Pharmaceutical Analysis and Quality Control from the University of London. She is the proud mother of two daughters and one son, and away from work she enjoys running and playing the piano and is a member of the Women Leaders Association (WLA) in the UK.